Author:
Dass Shouvik,Rawstron Andy C.,Vital Edward M.,Henshaw Karen,McGonagle Dennis,Emery Paul
Subject
Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy
Reference17 articles.
1. The biology of CD20 and its potential as a target for mAb therapy;Cragg;Curr Dir Autoimmun,2005
2. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum,2006
3. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial;Emery;Arthritis Rheum,2006
4. Relationship between clinical response, rituximab pharmacokinetics and peripheral B cell levels in rheumatoid arthritis;Breedveld;Ann Rheum Dis,2006
5. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens;Rawstron;Leukemia,2006
Cited by
181 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献